You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

281 Results
Statistical Reports
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Sacituzumab Govitecan - Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
New Drug Funding Program
    Sacituzumab Govitecan - HR-positive HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Jul 2025
Drug
Other Name(s): Trodelvy®
Jul 2025
Guidelines and Advice
Updated
Aug 2025

Pages